Berndr Seizinger News Today

HC Wainwright reissued their buy rating on shares of Aprea Therapeutics (NASDAQ:APRE – Free Report) in a research report released on Tuesday, Benzinga reports. The firm currently has a $20.00 price objective on the stock. HC Wainwright also issued estimates for Aprea Therapeutics’ Q2 2024 earnings at ($0.58) EPS, Q3 2024 earnings at ($0.56) EPS, […]

Aprea Therapeutics, Inc. (NASDAQ:APRE – Free Report) – Analysts at Wedbush reduced their FY2028 earnings per share estimates for Aprea Therapeutics in a research report issued to clients and investors on Tuesday, May 14th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of $0.77 per share for the year, down from […]

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 15, 2024 - AND - MANAGEMENT INFORMATION CIRCULAR ...

Aprea Therapeutics, Inc. (NASDAQ:APRE – Free Report) – Stock analysts at Wedbush issued their Q1 2025 earnings per share estimates for shares of Aprea Therapeutics in a research note issued to investors on Tuesday, March 26th. Wedbush analyst R. Driscoll forecasts that the company will post earnings of ($1.00) per share for the quarter. Wedbush […]

Aprea Therapeutics (NASDAQ:APRE – Free Report) had its price target boosted by Wedbush from $9.00 to $11.00 in a research note issued to investors on Wednesday morning, Benzinga reports. The firm currently has an outperform rating on the stock. Separately, HC Wainwright restated a buy rating and issued a $20.00 price target on shares of […]

StockNews.com upgraded shares of Aptose Biosciences (NASDAQ:APTO – Free Report) (TSE:APS) from a sell rating to a hold rating in a research note issued to investors on Monday. APTO has been the topic of several other reports. HC Wainwright increased their target price on Aptose Biosciences from $12.00 to $23.00 and gave the stock a […]

Aptose Biosciences (NASDAQ:APTO – Get Free Report) (TSE:APS) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Monday. Several other equities analysts also recently issued reports on APTO. HC Wainwright boosted their price target on shares of Aptose Biosciences from $12.00 to […]

Aptose Biosciences Inc. (NASDAQ:APTO – Get Free Report) (TSE:APS) was the recipient of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 41,900 shares, a growth of 37.8% from the October 15th total of 30,400 shares. Currently, 1.7% of the company’s shares are sold […]

Aptose Biosciences (NASDAQ:APTO – Get Free Report) (TSE:APS) had its price objective lowered by equities research analysts at Royal Bank of Canada from $23.00 to $18.00 in a report released on Friday, Benzinga reports. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. Several other brokerages have also recently issued reports on […]

Aptose Biosciences Inc. (NASDAQ:APTO – Get Free Report) (TSE:APS) has earned an average rating of “Buy” from the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have issued a report on the […]